Ironwood Pharmaceuticals, Inc. IRWD R2KR3KPHARMA
Company Overview
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Return on capital employed stands at 63.7%.
Revenue has grown at a 14.4% CAGR over the past five years.
Trades at a P/E of 4.4, below the sector median of 25.4.
Maintains a net profit margin of 33.4%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $296.15M (-15.7% YoY); net profit $24.02M.
- Trailing 12 Months Year-on-year growth — revenue +32.6%, earnings +125.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.4%, profit CAGR -25.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.42% |
| 1 Year: | 32.60% |
Compounded Profit Growth
| 5 Years: | -25.72% |
| 1 Year: | 125.70% |
Stock Price Performance
| 1 Year: | +217.43% |
| 6 Months: | -11.96% |
| 3 Months: | -11.51% |
| 1 Month: | -17.42% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.31 · Neutral
P/E of 4.38 is below the sector median of 25.45 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 63.7%.
- Excellent profit margin of 33.4%.
- Compounding revenue at 14.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -25.7% CAGR over 5 years.
- Trading 35.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IRWD Ironwood Pharmaceuticals, Inc. R2KR3KPHARMA | 3.46 | 4.38 | $571.73M | 0.00% | 63.68% | -9.17% | 14.42% | -25.72% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 52.17M | 65.08M | 86.83M | 94.21M | 69.16M | 81.11M | 65.69M | 130.69M | 68.73M | 102.22M | 131.17M | 126.30M | 79.94M | 89.43M | 103.47M | 116.68M | 88.84M | 104.03M | 103.75M | 117.13M | 97.53M | 97.23M | 108.64M | 107.20M | 104.06M | 107.38M | 113.74M | 117.55M | 74.88M | 94.40M | 91.59M | 90.55M | 41.14M | 85.24M | 122.06M | 47.71M | 106.51M | 113.04M |
| Operating Income | -28.29M | - | -39.70M | -41.01M | -19.43M | - | -35.87M | -14.68M | -146.57M | - | -16.93M | 21.58M | 65.89M | - | 13.23M | 32.71M | 45.62M | - | 45.40M | 65.10M | 65.17M | - | 57.85M | 55.66M | 68.47M | - | 60.10M | -1.08B | 40.02M | - | 11.02M | 24.98M | 25.64M | - | -29.11M | 45.32M | 75.48M | - | 72.57M | 79.31M |
| Net Income | -33.20M | -13.51M | -52.50M | -44.22M | -32.30M | 12.09M | -43.14M | -49.38M | -174.35M | -15.49M | -59.28M | 12.28M | 20.65M | 47.86M | 3.35M | 25.20M | 34.42M | 43.20M | 39.93M | 391.30M | 55.84M | 41.37M | 38.80M | 37.08M | 50.32M | 48.87M | 45.71M | -1.06B | 15.32M | -1.09M | -4.16M | -860.00K | 3.65M | 2.26M | -37.39M | 23.60M | 40.08M | -2.28M | 40.77M | 51.29M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.38 | 0.08 | 0.13 | 0.30 | 0.02 | 0.16 | 0.21 | 0.27 | 0.25 | 2.39 | 0.34 | 0.25 | 0.21 | 0.21 | 0.28 | 0.27 | 0.25 | -6.84 | 0.09 | -0.01 | -0.03 | -0.01 | 0.02 | 0.01 | -0.23 | 0.14 | 0.23 | -0.01 | 0.24 | 0.31 |
| R&D Expense | 37.53M | - | 33.70M | 37.34M | 37.06M | - | 36.51M | 23.19M | 29.16M | - | 32.20M | 28.76M | 27.55M | - | 28.03M | 22.08M | 21.69M | - | 15.48M | 12.16M | 10.91M | - | 10.82M | 11.45M | 11.54M | - | 12.85M | 34.58M | 32.98M | - | 25.82M | 30.39M | 29.83M | - | 27.43M | 23.37M | 22.47M | - | 21.94M | 22.42M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.32M | 43.86M | 65.87M | 150.25M | 22.88M | 76.44M | 149.56M | 273.96M | 298.28M | 346.64M | 428.41M | 389.52M | 413.75M | 410.60M | 442.74M | 351.41M | 296.15M |
| Operating Income | -60.82M | -60.77M | -66.14M | -72.76M | -252.00M | -169.37M | -102.09M | -51.87M | -15.36M | -150.67M | 120.12M | 142.94M | 232.26M | 250.34M | -945.43M | 93.12M | 98.50M |
| Net Income | -71.19M | -52.98M | -64.85M | -72.62M | -272.81M | -189.62M | -142.67M | -81.71M | -116.94M | -282.37M | 21.50M | 106.18M | 528.45M | 175.06M | -1.00B | 880.00K | 24.02M |
| Diluted EPS | - | - | -0.65 | -0.68 | -2.35 | - | - | - | - | -1.85 | 0.14 | 0.66 | 3.21 | 0.96 | -6.45 | 0.01 | 0.15 |
| R&D Expense | 76.10M | 77.45M | 86.09M | 113.47M | 102.38M | 101.89M | 108.75M | 139.49M | 88.14M | 101.06M | 115.04M | 88.06M | 70.41M | 44.27M | 116.08M | 111.42M | 95.14M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 301.37M | 208.98M | 229.91M | 278.96M | 329.32M | 619.12M | 709.82M | 605.67M | 332.05M | 402.75M | 559.24M | - | 1.10B | 471.07M | 350.91M | 396.90M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 780.63M | 233.29M | 182.37M | 274.18M |
| Cash & Equivalents | 66.33M | 122.31M | 44.32M | 87.28M | 136.70M | 75.49M | 74.30M | 261.29M | 54.00M | 125.74M | 173.17M | 177.02M | 362.56M | - | 656.20M | 92.15M | 88.56M | 215.46M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 115.46M | 129.12M | 81.89M | 46.74M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 448.14M | 817.37M | 652.24M | 658.74M |
| Current Liabilities | - | - | 64.43M | 65.13M | 54.94M | 41.04M | 60.54M | 76.47M | 91.13M | 66.03M | 119.52M | 40.93M | 32.17M | - | 25.52M | 276.10M | 38.85M | 242.22M |
| Long Term Debt | - | - | - | - | - | - | - | 220.62M | - | - | - | - | 430.26M | - | 396.25M | 498.31M | 583.99M | 385.00M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 415.92M | 715.54M | 599.48M | 597.80M |
| Total Equity | -230.41M | -298.34M | 159.55M | 109.86M | 144.05M | 38.23M | 88.55M | 95.12M | 66.72M | 9.85M | -196.37M | -93.25M | 62.64M | - | 652.38M | -346.30M | -301.33M | -261.83M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154.03M | 156.35M | 160.21M | 163.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.44M | -67.90M | -75.24M | -69.63M | -273.36M | -155.57M | -106.93M | -25.93M | -100.75M | -70.88M | 10.72M | 168.84M | 261.89M | 273.76M | 183.43M | 103.55M | 127.04M |
| Investing Cash Flow | 17.76M | -213.04M | 115.06M | 30.08M | -101.43M | -56.57M | -9.15M | -177.67M | 151.46M | 88.87M | -11.14M | -1.84M | -265.00K | -136.00K | -1.03B | -142.00K | -34.00K |
| Financing Cash Flow | 41.66M | 202.96M | 3.13M | 88.97M | 313.58M | 210.94M | 303.07M | -4.18M | 19.84M | 30.07M | -1.19M | 18.55M | -4.55M | -237.55M | 277.16M | -106.97M | 216.00K |
| Capital Expenditure | -3.52M | -17.22M | -9.68M | -13.98M | -9.59M | -3.54M | -4.05M | -4.21M | -2.80M | -351.00K | -7.19M | -1.84M | -265.00K | -136.00K | -273.00K | -142.00K | -34.00K |
| Free Cash Flow | -6.97M | -85.12M | -84.92M | -83.61M | -282.95M | -159.11M | -110.98M | -30.14M | -103.56M | -71.23M | 3.54M | 166.99M | 261.63M | 273.63M | 183.15M | 103.41M | 127.01M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 24.13M | 126.39M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -177.2% | -138.6% | -100.4% | -48.4% | -1,101.4% | -221.6% | -68.3% | -18.9% | -5.2% | -43.5% | 28.0% | 36.7% | 56.1% | 61.0% | -213.5% | 26.5% | 33.3% |
| Net Margin % | -207.4% | -120.8% | -98.5% | -48.3% | -1,192.3% | -248.1% | -95.4% | -29.8% | -39.2% | -81.5% | 5.0% | 27.3% | 127.7% | 42.6% | -226.4% | 0.3% | 8.1% |
| ROE % | 23.9% | -33.2% | -59.0% | -50.4% | -713.7% | -214.1% | -150.0% | -122.5% | -1,187.4% | 143.8% | -23.1% | 169.5% | - | 26.8% | 289.4% | -0.3% | -9.2% |
| ROCE % | - | -25.6% | -46.0% | -41.6% | -105.9% | -63.0% | -18.8% | -8.4% | -2.8% | -70.9% | 33.2% | 27.1% | - | 23.3% | -484.9% | 29.8% | 63.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.77% | 17.79M | $67.95M |
| 2 | Armistice Capital, LLC | 8.43% | 13.93M | $53.22M |
| 3 | Sarissa Capital Management, LP | 5.56% | 9.19M | $35.10M |
| 4 | State Street Corporation | 5.33% | 8.81M | $33.65M |
| 5 | Bank of America Corporation | 5.26% | 8.68M | $33.17M |
| 6 | Renaissance Technologies, LLC | 4.84% | 7.99M | $30.53M |
| 7 | Vanguard Capital Management LLC | 4.00% | 6.61M | $25.24M |
| 8 | AQR Capital Management, LLC | 3.91% | 6.47M | $24.70M |
| 9 | Acadian Asset Management. LLC | 3.54% | 5.85M | $22.36M |
| 10 | Vanguard Portfolio Management LLC | 3.34% | 5.51M | $21.06M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IRWD
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNQkNnbmxVdXU2ZnFnNURlN0pJVVBqT1R6U25RbFF3Y01pLTNhcFdISFg3ZjU3UzVCVG9MM0o3V1hBeDdDV3VMN21IMmZlQnVkLWIzWk8xVWhSbmMyQUhrVTFCbzRsWkFPWXdyYjRSckZ5M0g4V0JBekh5ZFFzcnVxLXJ5aXhmdjFiREJCeS…
Ironwood Pharma Announces CEO Transition and Leadership Changes - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQWkU4RkpHN29DVTRMX3JCRE5uRTRpRWRJX0tDQVFjR3llSU5oX0FCQU8tc3hyTFNaLVV5cVk1RGM0MlBuOG9ZbHVfbTNMQm0yb3NwSGdLdUxOYWZPZnhDajZNS2dQeDE5R2ZXRk1xTm4zOU5oekxKY0xCNkZWTlc4aC1mdUFCOTd4Mk5URT…
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity (NASDAQ:IRWD) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNMzllYUdBMXI2TktJYVFfY0hJNjN1MDBQX2JpX29rMkdJc0lhZzh0bVVvVlZBbWxVR1NxcmNPbzBUNVlrSGh6Y2dZSS13ODNZTS1sU3FoLW40N2hfOXFRUzRRRjVleEE1UFA0ZlZvaE1hcjV3SGI3Y3FRWUFSb3ktU0pBNlVyRnlkV3l4cX…
IRWD Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5kUzlaYTdkYkE3bTAxd0s5eTZtOWFrSzlfLUpyM2pFRnA3QWtIc3Qza3ExX2FRYUxrWHBPM1RHbHM5UjVfdkU2ZnpIaGZYOUpmNG9yYnBCSEtOTF9lZkhYOVJDYnBoYjNjc1RFZlFqSFlCODg4aUhxNlR3?oc=5" target="_blank">IRW…
Ironwood Pharmaceuticals stock falls on CEO transition news - Investing.com
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPbWhSSjJPdU9Vbk1vWGljZXFObUgtUGdPUUFNYjZaa3NBOU9QVlhNM2xoRl9oeXprVDFTcWRSNWw5SmRsTFpuSzNfMEswdjVWYWN5WFI4SW5FTkJUWTQtTXR0UG8zNng1TUw4MW83Y2pzVW0zNnNLd1M1QTZjMkk1Tnp6Ynk5UkJQXzZlcX…
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQVVB2cjJhbHgxRTM4UmFidDVOTm9oOVRYcGlJaEFGT3U1a0VwVHN6UjJ6ZEdPU3pWOFM2U1gtbk92bVA2N1FTQnFodnlIeHZhRWpDU3JjS05jcERmNFI1X1dYSGtJa29Wc3FYN09ZM3pZMERGUDNlSGtRb0FEdDJ1OFpKWTlKckN2SERVLU…
IRWD — Frequently Asked Questions
What is the current share price of Ironwood Pharmaceuticals, Inc. (IRWD)?
As of 2026-10-23 16:27 PDT, Ironwood Pharmaceuticals, Inc. (IRWD) trades at $3.46 on NasdaqGS. Its 52-week range is $1.03 to $5.39.
What is the market capitalisation of IRWD?
Ironwood Pharmaceuticals, Inc. (IRWD) has a market capitalisation of $571.73M on NasdaqGS.
What is the P/E ratio of IRWD?
IRWD trades at a trailing price-to-earnings (P/E) ratio of 4.38. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -4.45.
What is the return on equity (ROE) of IRWD?
IRWD has a return on equity (ROE) of -9.17%. Its return on capital employed (ROCE) is 63.68%.
Is IRWD a good stock to buy?
This page provides a data-driven analysis of Ironwood Pharmaceuticals, Inc. (IRWD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.